Show simple item record

dc.contributor.authorBoix-Palop, Lucía
dc.contributor.authorFernández, Tamara
dc.contributor.authorPelegrín, Iván
dc.contributor.authorObradors, Meritxell
dc.contributor.authorGarcía-Roulston, Kevin
dc.contributor.authorXercavins, Mariona
dc.contributor.authorGarcía-Somoza, Dolors
dc.contributor.authorArdanuy, Carmen
dc.contributor.authorGrau, Javier
dc.contributor.authorCalbo Sebastián, Esther
dc.contributor.authorCabellos, Carmen
dc.date.accessioned2021-05-13T15:28:26Z
dc.date.available2021-05-13T15:28:26Z
dc.date.issued2020-08
dc.identifier.citationBoix-Palop, Lucía; Fernández, Tamara; Pelegrín, Iván [et al.]. Delayed cerebral vasculopathy in pneumococcal meningitis: epidemiology and clinical outcome. A cohort study. International Journal of Infectious Diseases, 2020, 97, p. 283-289. Disponible en: <https://www.sciencedirect.com/science/article/pii/S1201971220304409?via%3Dihub>. Fecha de acceso: 13 may. 2021. DOI: 10.1016/j.ijid.2020.06.005ca
dc.identifier.issn1201-9712ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/2537
dc.description.abstractBackground: To describe the prevalence, clinical characteristics, impact of systemic steroids exposure and outcomes of delayed cerebral vasculopathy (DCV) in a cohort of adult patients with pneumococcal meningitis (PM). Methods: Observational retrospective multicenter study including all episodes of PM from January 2002 to December 2015. DCV was defined as proven/probable/possible based upon clinical criteria and pathological-radiological findings. DCV-patients and non-DCV-patients were compared by univariate analysis. Results: 162 PM episodes were included. Seventeen (10.5%) DCV-patients were identified (15 possible, 2 probable). At admission, DCV-patients had a longer duration of symptoms (>2 days in 58% vs. 25.5% (p 0.04)), more coma (52.9% vs. 21.4% (p 0.03)), lower median CSF WBC-count (243 cells/uL vs. 2673 cells/uL (p 0.001)) and a higher proportion of positive CSF Gram stain (94.1% vs. 71% (p 0.07)). Median length of stay was 49 vs. 15 days (p 0.001), ICU admission was 85.7% vs. 49.5% (p 0.01) and unfavorable outcome was found in 70.6% vs. 23.8% (p 0.001). DCV appeared 1-8 days after having completed adjunctive dexamethasone treatment (median 2,5, IQR = 1.5-5). Conclusions: One tenth of the PM developed DCV. DCV-patients had a longer duration of illness, were more severely ill, had a higher bacterial load at admission and had a more complicated course. Less than one third of cases recovered without disabilities. The role of corticosteroids in DCV remains to be established.en
dc.format.extent7ca
dc.language.isoengca
dc.publisherElsevierca
dc.relation.ispartofInternational Journal of Infectious Diseasesca
dc.relation.ispartofseries97;
dc.rights© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).en
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.otherMeningitisca
dc.subject.otherCervell -- Malaltiesca
dc.subject.otherPneumococsca
dc.subject.otherBacteriesca
dc.subject.otherMeningitises
dc.subject.otherCerebro -- Enfermedadeses
dc.subject.otherStreptococcus pneumoniaees
dc.subject.otherBacteriases
dc.subject.otherMeningitisen
dc.subject.otherBrain -- Diseasesen
dc.subject.otherPneumococcusen
dc.subject.otherBacteriaen
dc.titleDelayed cerebral vasculopathy in pneumococcal meningitis: epidemiology and clinical outcome. A cohort studyen
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.subject.udc616.8ca
dc.identifier.doihttps://dx.doi.org/10.1016/j.ijid.2020.06.005ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/